



Smartphone Biometric Health Assessment

JANUARY 2024



Scott Montgomery
Chief Executive Officer



Vlado Bosanac
Founder/Head of Strategy

Confidential – Do not duplicate or distribute without the written permission of Advanced Health Intelligence Ltd

This presentation (“Presentation”) has been prepared by **Advanced Health Intelligence Ltd** (“Advanced Health Intelligence” or “Company”).

You must read and accept the conditions in this notice before considering the information set out in or referred to in this Presentation. If you do not agree, accept or understand the terms on which this Presentation is supplied, or if you are subject to the laws of any jurisdiction in which it would be unlawful to receive this Presentation or which requires compliance with obligations that have not been complied with in respect of it, you must immediately return or destroy this Presentation and any other confidential information supplied to you by Advanced Health Intelligence. By accepting this document, you acknowledge and agree to the conditions in this notice and agree that you irrevocably release Advanced Health Intelligence from any claims you may have (presently or in the future) in connection with the provision or content of this Presentation.

NO OFFER

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction (and will not be lodged with the ASIC).

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares of Advanced Health Intelligence and does not and will not form any part of any contract for the acquisition of shares of Advanced Health Intelligence.

SUMMARY INFORMATION

This Presentation contains summary information about Advanced Health Intelligence, its subsidiaries and their activities which is current as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Advanced Health Intelligence or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act. While Advanced Health Intelligence has taken every effort to ensure the accuracy of the material in the presentation, neither the Company nor its advisers have verified the accuracy or completeness of the information, or any statements and opinion contained in this Presentation.

NOT INVESTMENT ADVICE

Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Advanced Health Intelligence and the impact that different future outcomes may have on Advanced Health Intelligence.

This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. Advanced Health Intelligence is not licensed to provide financial product advice in respect of Advanced Health Intelligence shares.

Cooling off rights do not apply to the acquisition of Advanced Health Intelligence shares.

INVESTMENT RISK

An investment in Advanced Health Intelligence shares is subject to known and unknown risks, some of which are beyond the control of Advanced Health Intelligence. Advanced Health Intelligence does not guarantee any particular rate of return or the performance of Advanced Health Intelligence nor does it guarantee any particular tax treatment. An investment in Advanced Health Intelligence should be considered as Highly Speculative and High Risk due to the start up nature of the Company and its proposed business.

FINANCIAL DATA

All dollar values in this Presentation are in Australian dollars (A\$ or AUD) unless otherwise stated.

FORWARD-LOOKING STATEMENTS

This Presentation may contain forward looking statements. The words 'anticipate', 'believe', 'expect', 'project', 'forecast', 'estimate', 'likely', 'intend', 'should', 'could', 'may', 'target', 'plan' and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. You should not place undue reliance on forward-looking statements and neither Advanced Health Intelligence nor any of its directors, employees, advisers or agents assume any obligation to update such information.

DISCLAIMER

None of Advanced Health Intelligence's respective advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorized, permitted or caused the issue, submission, dispatch or provision of this Presentation and, except to the extent referred to in this Presentation, none of them makes or purports to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by any of them.

To the maximum extent permitted by law, Advanced Health Intelligence and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in an investment in Advanced Health Intelligence and the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise.

To the maximum extent permitted by law, Advanced Health Intelligence and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation.

Statements made in this Presentation are made only as the date of this Presentation. The information in this Presentation remains subject to change without notice.



Biometric health screening using just a smartphone

no health professional or additional equipment required, not even a wearable.



Mission



Provide health monitoring access to every smartphone user globally.



Vision



Ubiquitous health monitoring



Advanced Health Intelligence (ASX–NASDAQ: AHI)
 Is a global digital health solution



Corporate overview

AHI sells its dHaaS (digital health-as-a-service) technology **to healthcare, insurance and government** customer segments around the world in a business-to-business model (**B-to-B**).

- **AHI completed two acquisitions in 2022, expanding** its capabilities to offer mass population health monitoring using only a user's smartphone.
- AHI holds **patents in Australia, USA, Japan, Korea, Singapore, New Zealand, China and Canada** and expects to add to the patent portfolio.
- **AHI screens for health risk stratification using only a smartphone by capturing biometric data**, including vital signs, body composition, dimension, and indicative blood markers. In addition, AHI offers DermaScan which covers 588 skin conditions across 133 categories.
- AHI enables its partners to estimate **41 biometrics across 5 health categories** in order to triage their users into directionalized care.

Issuer	Advanced Health Intelligence Ltd.
Exchange	Australian Securities Exchange (ASX), Nasdaq Capital Market (NASDAQ)
Shares on issue <small>As at 19 Jan 2024</small>	241,428,086 including ADR cover
NASDAQ ADR <small>ADR Ratio 28:1, As at 19th Jan 2024</small>	1,940,773
Employee headcount	34 across Australia, Singapore, USA, Canada, South Africa, Netherlands
Current partners addressable audience	> 250 million addressable users across AHI's current partners
Intellectual property	24 patents, across Australia, USA, Japan, Korea, Singapore, New Zealand, China And Canada



Recent announcements

120 days of momentum

5 January 2024:

Bearn Signs 3 New Partners Further Boosting AHI Shared Reven

28 December 2023:

AHI Secures \$2.27 million in R & D Tax Incentive Scheme

6 December 2023:

AHI Completes Formal Agreements with Pharmak Direct

30 November 2023:

AHI to Launch Medically Approved Mobile Phone-Based AF Asses

3 November 2023:


AHI Signs Binding Term Sheet with Vietnam Based OneClinic

21 September 2023:

AHI Signs LOI to Develop & Deploy a Digital Underwriting Solution

12 September 2023:

AHI Signs Collaboration Agreement with Abu Dhabi based Bin Farhood Group








The realities of the rising costs in healthcare

Global healthcare expenditure will reach 10% of GDP by 2040

The rising costs of healthcare have become a global challenge and a major reality for both developed and developing countries. According to the World Health Organization (WHO), the global healthcare expenditure is projected to reach 10% of the Gross Domestic Product (GDP) by the year 2040⁴.

By streamlining health assessment and triage into a smartphone experience, AHI offers pathways into improving population health literacy and empowering individuals to take better control of their health.



Sources

1. How many smartphones are in the world?, <https://bankmycell.com/>
2. Noncommunicable diseases, <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases/>
3. Facts about Hypertension in the United States, <https://cdc.gov>
4. Global spending on health: Weathering the storm <https://www.who.int/publications/i/item/9789240017788>



Trends in digital health

Healthcare is increasingly powered by AI

“ Major tech vendors continuously compete to upgrade their AI platforms with regular enhancements, as projections show the global healthcare AI market will reach nearly **188 billion U.S. dollars by 2030**¹ ”

Forbes



Med-PaLM 2 reached **86.5% accuracy** on the MedQA medical exam benchmark in research in line with a medical expert. The general pass mark is ~60%²



FDA Clearance Granted for First AI-Powered Medical Device to Detect All Three Common Skin Cancers (Melanoma, Basal Cell Carcinoma and Squamous Cell Carcinoma)³

Sources

1. <https://www.forbes.com/sites/davidchou/2023/12/17/google-launches-a-healthcare-focused-llm/?sh=4c37ca7d729c>
2. <https://sites.research.google/med-palm/>
3. <https://www.dermasensor.com/fda-clearance-granted-for-first-ai-powered-medical-device-to-detect-all-three-common-skin-cancers-melanoma-basal-cell-carcinoma-and-squamous-cell-carcinoma/>



Trends in digital health

More prevalence means more access

62% of smartphone users use their phone for mHealth.

A more common smartphone activity than online banking (57%), job searches (42%)^{1,2}.


< 6%

of the world's adults use a wearable².



90%

of the world's adults use a smartphone².



Sources:

¹<https://www.sciencedirect.com/science/article/abs/pii/S1934148217303829>

²<https://mobius.md/2021/10/25/11-mobile-healthstatistics/#:~:text=Most%20smartphone%20users%20have%20used,5>

²<https://www.statista.com/forecasts/1143723/smartphone-users-in-the-world>



Realising digital transformation in healthcare

Biometric health assessment for global populations

Our aim is to revolutionize healthcare with our proprietary technology. This scalable technology allows the convenient and cost-effective distribution of health assessments to derive real-time risk stratification and automate digital triage at population-scale with improved accuracy.

Our comprehensive suite of digital health solutions creates a cohesive ecosystem that supports healthcare success, addressing the Triple Aim.



01

Population health assessments and engagement

Provide scalable access and automation through smartphones to easily assess health vital signs without need for more devices or health professionals.

Very low cost per person Entire population



02

Targeted digital interventions

Personalized eHealth programs for targeted outcomes (i.e. the opposite of one-size-fits-all public health).

Very low cost per person

People identified as high risk of selected illness



03

Telehealth or physician consultation for condition management

Where clinically appropriate, referrals into partner-selected telehealth and physician clinics.


Varies by provider

People diagnosed with selected illnesses

Our solutions

Proactive risk management in the palm of your hand

- ✓ **All on the smartphone in less than 15 minutes** – no additional wearables or hardware needed.
- ✓ **Remote and contactless** biometric-derived health assessment for risk estimates associated with blood pressure, heart rate, HbA1c, cholesterol, (LDL and HDL), triglycerides and many more.
- ✓ **Wide range of predicted health risks** including obesity, heart attack risk, stroke risk, 10-year Framingham cardiovascular disease risk, diabetes and more.
- ✓ **Seamless triage capability** - lower risk individuals can be referred into subclinical care options while moderate to higher risk can be referred into telehealth or higher care options.





Biometric health assessment

4-scans in less than 15-minutes for a biometric health report

01. Cardiovascular and mental health

FaceScan uses facial blood flow analysis to deliver health vital estimates including blood pressure, heart rate, heart rate variability and breathing rate. This is promptly followed by the GAD7 and PHQ9, the clinical standard for anxiety and depression risk detection.

02. Health at rest


Health at rest focusses on the cardiovascular system and predicts resting heart rate risk. FingerScan employs Photoplethysmography (PPG) technology to detects volumetric changes in blood in peripheral circulation while at rest.

03. Body dimension and composition

BodyScan is built with proprietary computer vision and machine learning processing modules, which use over 1,000's data points to generate and guide the scaled contour. This returns estimates on body dimension and composition, such as body fat %, waist hip ratio, and waist height ratio, comparable to gold standard methods.

04. Post exertion recovery

A 3-minute step test promptly followed by a FingerScan PPG to review cardiovascular fitness. This evenly paced stepping exercise reviews the associated risks with heart rate recovery and heart disease.



What's included in the report?

Estimations include:

- 📦 Cardiorespiratory fitness
- 📦 10-year cardiovascular disease risk
- 📦 Framingham 10-year hard cardiovascular disease risk
- 📦 Resting heart rate
- 📦 Systolic blood pressure
- 📦 Diastolic blood pressure
- 📦 Blood sugar
- 📦 Body fat percentage
- 📦 Waist circumference
- 📦 Hip circumference
- 📦 Waist-to-hip ratio
- 📦 Waist-to-height ratio
- 📦 Body mass index
- 📦 General anxiety
- 📦 Depression
- 📦 Arterial stiffness
- 📦 Visceral adiposity index
- 📦 Lipid accumulation product
- 📦 Blood lipids
- 📦 LDL Cholesterol
- 📦 HDL Cholesterol
- 📦 Triglycerides
- 📦 C-reactive protein inflammation



Biometric health assessment

4-scans in less than 15-minutes for a biometric health report

01. Cardiovascular and mental health

FaceScan uses facial blood flow analysis to deliver health vital estimates including blood pressure, heart rate, heart rate variability and breathing rate. This is promptly followed by the GAD7 and PHQ9, the clinical standard for anxiety and depression risk detection

02. Health at rest


Health at rest focusses on the cardiovascular system and predicts resting heart rate risk. FingerScan employs Photoplethysmography (PPG) technology to detect volumetric changes in blood in peripheral circulation while at rest

03. Body dimension and composition

BodyScan is built with proprietary computer vision and machine learning processing modules, which use over 1,000's of data points to generate and guide the scaled contour. This returns estimates on body dimension and composition, such as body fat %, waist hip ratio, and waist height ratio, comparable to gold standard methods

04. Post exertion recovery

A 3-minute step test promptly followed by a FingerScan PPG to review cardiovascular fitness. This evenly paced stepping exercise reviews the associated risks with heart rate recovery and heart disease



What's included in the report?

Estimations include:

- 📦 Cardiorespiratory fitness
- 📦 10-year cardiovascular disease risk
- 📦 Framingham 10-year hard cardiovascular disease risk
- 📦 Resting heart rate
- 📦 Systolic blood pressure
- 📦 Diastolic blood pressure
- 📦 Blood sugar
- 📦 Body fat percentage
- 📦 Waist circumference
- 📦 Hip circumference
- 📦 Waist-to-hip ratio
- 📦 Waist-to-height ratio
- 📦 Body mass index
- 📦 General anxiety
- 📦 Depression
- 📦 Arterial stiffness
- 📦 Visceral adiposity index
- 📦 Lipid accumulation product
- 📦 Blood lipids
- 📦 LDL cholesterol
- 📦 HDL cholesterol
- 📦 Triglycerides
- 📦 C-reactive protein inflammation



Biometric health assessment

Bloodless. Biometric. Ubiquitous.

- 61 outputs
- 41 biometrics
- 5 health categories

Self administered biometric health assessment from a user's own smartphone, no supporting equipment or health professional required

Helping scale GPs' health-monitoring for larger populations

Health Risk Assessment



About You

Age	Weight	Height	Biological Sex	Smoker Status
63	72	168 cm	Male	No

Cardiorespiratory Health

Resting Heart Rate **75 bpm**

Cardiorespiratory Fitness

Cardiorespiratory Fitness is the ability of the heart and lungs supporting working muscles during exercise. It is measured as a maximum amount of oxygen a person can consume during exercise.

Your Cardiorespiratory Fitness estimate is good.

10-Year Cardiovascular Disease Risk

Based on resting heart rate, BMI, age, gender, smoker status studies.

You have an estimated 7% chance of developing Cardiovascular Disease in the next 10 years.

Framingham 10-Year Hard Cardiovascular Disease Risk

Calculated using the Framingham Coronary Heart Disease Risk

You have an estimated 10% chance of having a heart attack in the next 10 years.

Blood Pressure

Uncontrolled high blood pressure can increase the risk of heart kidney disease and vision loss.

Systolic Blood Pressure **118 mm Hg**

Indicates how much pressure your blood is exerting against your artery walls. Systolic Blood Pressure is a major risk factor for cardiovascular disease, and typically increases with age.

Diastolic Blood Pressure **76 mm Hg**

Indicates how much pressure your blood is exerting against your artery walls while resting.

Your blood pressure estimate is normal.

Blood Sugar

Prolonged high blood glucose levels can increase the risk of heart disease, kidney and vision problems.

Blood Sugar Estimation

An estimation of % HbA1c in your bloodstream is an indicator of your blood sugar control.

Your blood sugar estimate is normal.

Body Dimensions

Waist Circumference: 83.5 cm

Hip Circumference: 94.5 cm

Waist to Hip Ratio: **0.88**

Waist to Height Ratio: **0.5**

Body Fat Percentage

High percentage body fat increases your risk of obesity related diseases such as heart disease, high blood pressure, stroke and type-2 diabetes.

Body Mass Index

Body Mass Index is a risk indicator for obesity related cardiovascular diseases such as high blood pressure, osteoarthritis, some cancers and diabetes.

Your estimated central obesity risk is low.

Mental Health

General Anxiety

Increases risk of high blood pressure and heart disease. If you have heart disease, anxiety disorders may increase the risk of coronary events.

Your general anxiety estimate is low.

Depression

Increases risk of developing inflammation, diabetes, osteoporosis and heart disease.

Your depression estimate is low.

Metabolic Health

Metabolic syndrome includes at least 3 of the following:

- High blood pressure
- High blood sugar
- Excess body fat around the waist
- Abnormal total cholesterol and high-density lipoprotein levels, which increases the risk of heart attack and stroke.

Arterial Stiffness

The elasticity of your arteries determine the circulation workload on your heart. Arterial stiffness increases with age, and increases the workload on the heart. Arterial stiffness is associated with increased blood pressure and insulin resistance. We estimate your Brachial-ankle pulse wave velocity (baPWV) as an indicator of arterial stiffness, used with your estimated lipid data to predict your risk for metabolic syndrome.

Visceral Adiposity Index

Excessive visceral fat results from a lack of exercise and excessive food intake. It is stored deep inside the belly, around your organs. The visceral adiposity index is an indicator of your cardio-metabolic risk based on your sex, body composition and blood lipids.

Lipid Accumulation Product

The over-accumulation of lipids in your muscles and liver increases your risk of type 2 diabetes and heart disease.

Blood Lipids

Total Cholesterol: a measure of all your blood cholesterol components that indicate your risk of heart disease.

LDL Cholesterol: can build up on the walls of your arteries and increase your risk of heart disease. The lower your LDL-C concentration, the lower your risk.

HDL Cholesterol: protects against disease and prevents LDL buildup in the arteries. A higher HDL-cholesterol concentration may lower your risk of heart disease.

Triglycerides: high triglycerides increase the risk of stroke, heart attack, and heart disease. It is also a risk indicator for metabolic syndrome.

Your blood lipid estimate is normal.

Inflammation

Inflammation is associated with stroke, chronic respiratory diseases, heart disorders, cancer, obesity, and diabetes. C-reactive protein in your bloodstream is an indicator of inflammation.

C-reactive protein estimate **0.42 mg/L**

Your inflammation estimate is normal.



Biometric health assessment

Triage into the right care pathways


Promote early-risk detection and encourage sooner actions.

Trigger a referral into higher-care, including telemedicine and telehealth based on a higher-risk indication from the biometric health assessment.


Meanwhile lower-risk triggers can be referred into subclinical care options for general health maintenance.



10-minute biometric health assessment





The results detect a potential elevated risk of hypertension and anxiety. All other vitals and risks reported as normal.




Risk stratifications offer recommended care pathways.



A telehealth consult is recommended to address the hypertension predicted risk.



Meanwhile for lower risk or predicted health risks that can be monitored, you can connect to health programs or subclinical options.





Our solutions

Validation



AHI is rapidly closing the gap to blood-based point-of-care testing.

Early results from first pool of subjects comparing AHI's BHA accuracy to gold standard measurements.

- **99.7%** accuracy resting heart rate to 3-lead ECG
- **95%** accuracy Lipid Accumulation Product (LAP) to blood draw
- **90.5%** accuracy waist-height ratio to biokineticist measure
- **85%** accuracy Metabolic Syndrome (MetS) to blood draw
- **85%** accuracy LDL Cholesterol to blood draw
- **83%** accuracy Total Cholesterol to blood draw



Research-led, science backed and published globally

The research and studies associated with the efficacy of our technologies has been featured in luminary publications.



Agreement of anthropometric and body composition measures predicted from 2D smartphone images and body impedance scales with criterion methods



DXA reference values and anthropometric screening for visceral obesity in Western Australian adults.



Obesity and visceral fat in Indonesia; An unseen epidemic? A study using iDXA and surrogate anthropometric measures.



Smartphone derived body composition and anthropometry for tracking weight loss



Artificial Intelligence in the Evaluation of Telemedicine Dermatology Patients



Longitudinal concordance of body composition and anthropometric assessment by a novel smartphone application across a 12-week self-managed weight loss intervention



The Hidden Public Health Problem of Inadequate Sleep: Deploying Digital Mobile Technology to Improve Employee Sleep Hygiene in Asia



High Impact Employee Stress Reduction and Wellness Promotion Delivered via Digital Mobile Technology in the Construction and Aviation Industries



No retrenchment from employee empowerment Employer wellness imperatives and opportunities emerging from the COVID-19 pandemic.



Employee Wellness in a Changing Climate: Environmental Heat Stress Driving Need for Targeted Health Promotion and Risk Reduction



Contextual wellness in the age of COVID-19: Managing disproportionate pandemic anxiety and stress in Australia, Singapore and other nations achieving disease control success.



Superiority of Artificial Intelligence in the Diagnostic Performance of Malignant Melanoma Compared to Dermatologists and Primary Care Providers



New solutions

Atrial Fibrillation SaMD to launch Q2-2024



AHI plans to release Software-as-a-Medical-Device (SaMD) Atrial Fibrillation scan as part of its Biometric health assessment (BHA) from Q2-2024, as well as the Atrial Fibrillation scan a stand-alone service.

The PPG fingerscan is a function of phase 2 and phase 4 of AHI's BHA and will soon offer medically approved atrial-fibrillation detection.


The technology has medical approval in **Australia, USA, Singapore, EU, UK, UAE and Saudi Arabia** for near clinical.

The global prevalence of atrial fibrillation (AF) is approximately **60 million cases**, of which up to 40% AF patients are asymptomatic.



Global, private and secure.

We collaborate with our partners to establish a shared responsibility model, to ensure our digital health solutions comply with applicable regulations in those territories including HIPAA*, GDPR and more. This model ensures that sensitive health information is effectively protected at all touch points. Furthermore, Data Processing Agreements outlining the requirements and obligations we undertake are entered into with partners to ensure global privacy standards are met and maintained. Our technology meets OWASP standards and is consistently reviewed by independent security experts.




-  No images or videos leave the device
-  Only encrypted data-signals are sent to the cloud for processing and analysis
-  Users choose who to share results with and when

* HIPAA compliance applies to FaceScan and BodyScan data processing.




Simple and scalable for global populations

AHI Biometric Scans



SDK Integration




Scalable Care

More Health Screenings

Earlier risk Detection

Health Literacy

Earlier Intervention



Integrated Care Solution

Using AHI's Integrated Enterprise Software Platform

Engagement layer

Single digital interface for Payor and Patient.

Data and analytics

Rich patient database to drive burden of disease progression and health predictions.


Software Solutions

Technology-based on international standards of interoperability with health databases and EHR.

Reporting

Payors population based on epidemiological predictive surveillance, risk dashboards and spend patterns.

Software Solutions






Our positioning

Customer segments & ROI

Payor ROI – why customers buy dHaaS:

1. **Reduced cost and risk** (through early detection and intervention opportunities)
2. **Improved health and care outcomes**
3. **Process automation** (HR, health care providers)
4. **Data** – better understand customer needs, improving sales of core goods/services better



Sources

1. <https://www.globenewswire.com/en/news-release/2022/04/11/2420173/0/en/Worldwide-3-Trillion-Health-Insurance-Market-Size-is-Expected-to-Grow-at-a-CAGR-of-over-4-4-During-2022-2028-Vantage-Market-Research.html>
2. <https://www.mordorintelligence.com/industry-reports/global-life-and-non-life-insurance-market-growth-trends-and-forecast-2020-2025>

3. <https://www.businesswire.com/news/home/20190625005862/en/The-11.9-Trillion-Global-Healthcare-Market-Key-Opportunities-Strategies-2014-2022---ResearchAndMarkets.com>
4. <https://stats.oecd.org/Index.aspx?DataSetCode=SHA>
5. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695957/>

Engaged customers

AHI has the below current partners who represent a total addressable audience of over 250 million people.

AHI is working with each of these partners to complete technical integration and launch to these audiences in Q1 and Q2-2024.

Every engaged user attracts AHI license fees.



TRUCONNECT



IntelliGen



Our network of partners and customers represent

250 million

potential users



Business Targets in H1-2024

1 LAUNCH AT LEAST 4 COMMERCIAL PARTNERS

Bearn - *USA*
OneClinic - *Vietnam*
Pharmak - *UAE*
Upvio - *USA, Asia*

2 CLOSE AT LEAST 2 MAJOR PIPELINE PROSPECTS

China
Vietnam
South East Asia
Middle East

3 SaMD CERTIFICATION

Clinical or near-clinical use

AHI are in discussions with strategic partners and investors, we welcome your conversation.

Thank-you



Scott Montgomery
Chief Executive Officer
investor@ahi.tech



Vlado Bosanac
Founder/Head of Strategy
investor@ahi.tech

For more information on how Advanced Health Intelligence how our technologies can help you, find out more at <https://ahi.tech>



Corporate Headquarters
Suite 5, 71-73 South Perth
Esplanade,
South Perth WA 6151
hello@ahi.tech

Other locations / Asia Pacific: Perth, Melbourne, Sydney, Singapore
North America: Vancouver, Denver **South Africa:** Cape Town
Europe: Amsterdam